0000313616-22-000005.txt : 20220127 0000313616-22-000005.hdr.sgml : 20220127 20220126174642 ACCESSION NUMBER: 0000313616-22-000005 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20220127 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220127 DATE AS OF CHANGE: 20220126 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DANAHER CORP /DE/ CENTRAL INDEX KEY: 0000313616 STANDARD INDUSTRIAL CLASSIFICATION: INDUSTRIAL INSTRUMENTS FOR MEASUREMENT, DISPLAY, AND CONTROL [3823] IRS NUMBER: 591995548 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-08089 FILM NUMBER: 22559034 BUSINESS ADDRESS: STREET 1: 2200 PENNSYLVANIA AVE. N.W. STREET 2: SUITE 800W CITY: WASHINGTON STATE: DC ZIP: 20037-1701 BUSINESS PHONE: 2028280850 MAIL ADDRESS: STREET 1: 2200 PENNSYLVANIA AVE. N.W. STREET 2: SUITE 800W CITY: WASHINGTON STATE: DC ZIP: 20037-1701 FORMER COMPANY: FORMER CONFORMED NAME: DMG INC DATE OF NAME CHANGE: 19850221 8-K 1 dhr-20220127.htm 8-K dhr-20220127
false000031361600003136162022-01-272022-01-270000313616us-gaap:CommonStockMember2022-01-272022-01-270000313616us-gaap:SeriesAPreferredStockMember2022-01-272022-01-270000313616us-gaap:SeriesBPreferredStockMember2022-01-272022-01-270000313616dhr:FloatingRateSeniorNotesDue2022Member2022-01-272022-01-270000313616dhr:A1.7SeniorNotesDue2024Member2022-01-272022-01-270000313616dhr:A0.2SeniorNotesDue2026Member2022-01-272022-01-270000313616dhr:A2.1SeniorNotesDue2026Member2022-01-272022-01-270000313616dhr:A1.2SeniorNotesDue2027Member2022-01-272022-01-270000313616dhr:A0.45SeniorNotesDue2028Member2022-01-272022-01-270000313616dhr:A2.5SeniorNotesDue2030Member2022-01-272022-01-270000313616dhr:A0.75SeniorNotesDue2031Member2022-01-272022-01-270000313616dhr:A1.35SeniorNotesDue2039Member2022-01-272022-01-270000313616dhr:A1.8SeniorNotesDue2049Member2022-01-272022-01-27

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________
FORM 8-K
__________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): January 27, 2022
__________________
dhr-20220127_g1.jpg
DANAHER CORPORATION
(Exact Name of Registrant as Specified in Its Charter)
__________________
Delaware001-0808959-1995548
(State or Other Jurisdiction of Incorporation)(Commission File Number)(IRS Employer Identification No.)
2200 Pennsylvania Avenue, N.W., 20037-1701
Suite 800W
Washington,DC
(Address of Principal Executive Offices) (Zip Code)
202-828-0850
(Registrant’s Telephone Number, Including Area Code)
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
__________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, $0.01 par valueDHRNew York Stock Exchange
4.75% Mandatory Convertible Preferred Stock, Series A, without par valueDHR.PRANew York Stock Exchange
5.00% Mandatory Convertible Preferred Stock, Series B, without par valueDHR.PRBNew York Stock Exchange
Floating Rate Senior Notes due 2022DHR/22ANew York Stock Exchange
1.700% Senior Notes due 2024DHR 24New York Stock Exchange
0.200% Senior Notes due 2026DHR/26New York Stock Exchange
2.100% Senior Notes due 2026DHR 26New York Stock Exchange
1.200% Senior Notes due 2027DHR/27New York Stock Exchange
0.450% Senior Notes due 2028DHR/28New York Stock Exchange
2.500% Senior Notes due 2030DHR 30New York Stock Exchange
0.750% Senior Notes due 2031DHR/31New York Stock Exchange
1.350% Senior Notes due 2039DHR/39New York Stock Exchange
1.800% Senior Notes due 2049DHR/49New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 





ITEM 2.02RESULTS OF OPERATIONS AND FINANCIAL CONDITION
On January 27, 2022, Danaher Corporation (“Danaher”) issued a press release announcing financial results for the year ended December 31, 2021. A copy of the release is furnished herewith as Exhibit 99.1 and incorporated by reference herein. This Current Report on Form 8-K and the press release attached hereto are being furnished by Danaher pursuant to Item 2.02 of Form 8-K.
This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

ITEM 9.01FINANCIAL STATEMENTS AND EXHIBITS
(c)Exhibits:
Exhibit No.  Description
99.1   
104 The cover page from this Current Report on Form 8-K, formatted as Inline XBRL.



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
DANAHER CORPORATION
Date:January 26, 2022By:/s/ Matthew R. McGrew
Matthew R. McGrew
Executive Vice President and Chief Financial Officer


 EX-99.1 2 dhr-20220127xex991.htm EX-99.1 Document

Exhibit 99.1
dhrlogofor8ksa62.jpg

DANAHER REPORTS FOURTH QUARTER AND FULL YEAR 2021 RESULTS
WASHINGTON, D.C., January 27, 2022 -- Danaher Corporation (NYSE: DHR) (the “Company”) today announced results for the fourth quarter and full year 2021. All results in this release reflect only continuing operations unless otherwise noted.
For the quarter ended December 31, 2021, net earnings were $1.8 billion, or $2.39 per diluted common share which represents a 44.0% year-over-year increase from the comparable 2020 period.
Non-GAAP adjusted diluted net earnings per common share were $2.69 which represents a 29.0% increase over the comparable 2020 period. For the fourth quarter 2021, revenues increased 20.5% year-over-year to $8.1 billion, with 19.5% non-GAAP core revenue growth.
For the full year 2021, net earnings were $6.3 billion, or $8.50 per diluted common share which represents a 74.0% year-over-year increase. Non-GAAP adjusted diluted net earnings per common share for 2021 were $10.05 per share, which represents a 59.0% increase over the comparable 2020 amount. Revenues for the full year 2021 increased 32.0% to $29.5 billion, with 25.0% non-GAAP core revenue growth including Cytiva.
Operating cash flow for the full year 2021 was $8.4 billion, representing a 34.5% increase year-over-year, and non-GAAP free cash flow was $7.1 billion, representing a 30.5% increase year-over-year.
Rainer M. Blair, President and Chief Executive Officer, stated, “2021 was a tremendous year for Danaher. Our team successfully executed through a challenging environment to deliver outstanding financial results — including 25% core revenue growth, nearly 60% adjusted earnings per share growth and over $7 billion of free cash flow. We were particularly pleased with the performance in our base business, which grew low-double digits, and believe we gained market share across our portfolio. We also continued to build for the future, deploying $11 billion on strategic acquisitions while accelerating innovation and capacity investments.”
Blair continued, “Over the last several years, our portfolio has undergone a significant, purpose-driven transformation. We’re a better, stronger company today, comprised of high-quality, market-leading franchises in attractive end-markets. We believe the combination of our exceptional portfolio, talented team and the Danaher Business System provides a strong foundation for 2022 and beyond.”
Starting with the first quarter 2022, in addition to presenting GAAP revenue growth, the Company will present base business core revenue growth that includes the impact of COVID-19 vaccine and therapeutic related revenue and excludes the impact of COVID-19 testing revenue.
For both the first quarter and full year 2022, the Company anticipates that non-GAAP core revenue growth in the base business will be in the high-single digit percent range.
Danaher will discuss its results during its quarterly investor conference call today starting at 8:00 a.m. ET. The call and an accompanying slide presentation will be webcast on the “Investors” section of Danaher’s website, www.danaher.com, under the subheading “Events & Presentations.” A replay of the webcast will be available in the same section of Danaher’s website shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call.
The conference call can be accessed by dialing 800-895-3361 within the U.S. or by dialing +1-785-424-1062 outside the U.S. a few minutes before the 8:00 a.m. ET start and telling the operator that you are dialing in for Danaher’s earnings conference call (conference ID: DHRQ421). A replay of the conference call will be available shortly after the conclusion of the call and until February 10, 2022. You can access the replay dial-in information on the “Investors” section of Danaher’s website under the subheading “Events & Presentations.” In addition, presentation materials relating to Danaher’s results have been posted to the “Investors” section of Danaher’s website under the subheading “Quarterly Earnings.”
ABOUT DANAHER
Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world. Its family of world class brands has leadership positions in the demanding and attractive health care, environmental and applied end-markets. With more than 20 operating companies, Danaher’s globally diverse team of approximately 80,000 associates is united by a common culture and operating system, the Danaher Business System, and its Shared Purpose, Helping Realize Life’s Potential. For more information, please visit www.danaher.com.
1

NON-GAAP MEASURES
In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings release also contains non-GAAP financial measures. Calculations of these measures, the reasons why we believe these measures provide useful information to investors, a reconciliation of these measures to the most directly comparable GAAP measures, as applicable, and other information relating to these non-GAAP measures are included in the supplemental reconciliation schedule attached.
FORWARD-LOOKING STATEMENTS
Statements in this release that are not strictly historical, including the statements regarding the Company's expected financial performance for the first quarter and full year 2022, the Company’s positioning and prospects for the future and any other statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things, the highly uncertain and unpredictable severity, magnitude and duration of the COVID-19 pandemic (and the related governmental, business and community responses thereto) on our business, results of operations and financial condition, the impact of our debt obligations (including the debt incurred to finance the acquisitions of Cytiva and Aldevron) on our operations and liquidity, deterioration of or instability in the economy, the markets we serve and the financial markets (including as a result of the COVID-19 pandemic), uncertainties relating to U.S. laws or policies, including potential changes in U.S. trade policies and tariffs and the reaction of other countries thereto, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including rules relating to off-label marketing and other regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and consummate appropriate acquisitions and strategic investments and successfully complete divestitures and other dispositions, our ability to integrate the businesses we acquire and achieve the anticipated benefits of such acquisitions (including with respect to the acquisition of Aldevron), our ability to realize anticipated growth, synergies and other benefits of the Aldevron acquisition, Aldevron's performance and maintenance of important business relationships, contingent liabilities and other risks relating to acquisitions, investments, strategic relationships and divestitures (including tax-related and other contingent liabilities relating to past and future IPOs, split-offs or spin-offs), security breaches or other disruptions of our information technology systems or violations of data privacy laws, the impact of our restructuring activities on our ability to grow, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, the rights of the United States government to use, disclose and license certain intellectual property we license if we fail to commercialize it, risks relating to product, service or software defects, product liability and recalls, risks relating to product manufacturing, our relationships with and the performance of our channel partners, uncertainties relating to collaboration arrangements with third-parties, commodity costs and surcharges, our ability to adjust purchases and manufacturing capacity to reflect market conditions, reliance on sole sources of supply, the impact of deregulation on demand for our products and services, labor matters, international economic, political, legal, compliance, social and business factors (including the impact of the United Kingdom's separation from the EU), disruptions relating to man-made and natural disasters (including pandemics such as COVID-19) and pension plan costs. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2020 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the third quarter of 2021. These forward-looking statements speak only as of the date of this release and except to the extent required by applicable law, the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.
CONTACT
Matthew E. Gugino
Vice President, Investor Relations and FP&A
Danaher Corporation
2200 Pennsylvania Avenue, N.W., Suite 800W
Washington, D.C. 20037
Telephone: (202) 828-0850
Fax: (202) 828-0860
2

DANAHER CORPORATION
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
Adjusted Diluted Net Earnings Per Common Share from Continuing Operations 1
 Three-Month Period Ended Year Ended
December 31, 2021December 31, 2020December 31, 2021December 31, 2020
Diluted Net Earnings Per Common Share From Continuing Operations (GAAP)$2.39 $1.66 $8.50 $4.89 
Amortization of acquisition-related intangible assets A
0.53 0.45 1.95 1.55 
Acquisition-related items B
0.02 0.06 0.14 0.77 
Impairments C
— — 0.01 0.03 
Fair value net (gains) losses on investments D
(0.10)(0.04)(0.54)(0.02)
Gain on disposition of certain product lines E
— — (0.02)(0.62)
Contract settlement expense F
— — 0.73 — 
Loss on early extinguishment of debt G
0.13 0.04 0.13 0.04 
Tax effect of the above adjustments H
(0.12)(0.10)(0.51)(0.27)
Discrete tax adjustments I
(0.16)— (0.35)(0.12)
MCPS "as if converted" J
— 0.01 0.01 0.06 
Adjusted Diluted Net Earnings Per Common Share From Continuing Operations (Non-GAAP)$2.69 $2.08 $10.05 $6.31 
1    Each of the per share adjustment amounts above have been calculated assuming the Mandatory Convertible Preferred Stock (“MCPS”) had been converted into shares of common stock.
Adjusted Average Common Stock and Common Equivalent Diluted Shares Outstanding
(shares in millions)
Three-Month Period EndedYear Ended
December 31, 2021December 31, 2020December 31, 2021December 31, 2020
Average common stock and common equivalent shares outstanding - diluted (GAAP) 2
738.4 724.5 736.8 718.7 
Converted shares 3
8.6 19.6 8.6 17.1 
Adjusted average common stock and common equivalent shares outstanding - diluted (non-GAAP)747.0 744.1 745.4 735.8 
2    The impact of the MCPS Series A calculated under the if-converted method was dilutive for the three-month period and year ended December 31, 2021, and as such 11.0 million shares underlying the MCPS Series A were included in the calculation of diluted EPS in both periods and the related MCPS Series A dividends of $20 million and $78 million were excluded from the calculation of net earnings for diluted EPS for the respective periods.
The impact of the MCPS Series B calculated under the if-converted method was anti-dilutive for the three-month period and year ended December 31, 2021, and as such 8.6 million shares underlying the MCPS Series B were excluded from the diluted EPS calculation in both periods and the related MCPS Series B dividends of $21 million and $86 million were included in the calculation of net earnings for diluted EPS for the respective periods.
The impact of the MCPS Series A and MCPS Series B calculated under the if-converted method was anti-dilutive for the three-month period and year-ended December 31, 2020, and as such, 19.6 million shares and 17.1 million shares, respectively underlying the MCPS Series A and Series B were excluded from the calculation of diluted EPS for the periods and the related MCPS Series A and Series B dividends of $41 million and $136 million, respectively, were included in the calculation of net earnings for diluted EPS for the periods.
3    The number of converted shares assumes the conversion of all MCPS and issuance of the underlying shares applying the “if-converted” method of accounting and using an average 20 trading-day trailing volume weighted average price (“VWAP”) of $316.06 and $223.43 as of December 31, 2021 and December 31, 2020, respectively.

See the accompanying Notes to Reconciliation of GAAP to Non-GAAP Financial Measures
3

DANAHER CORPORATION
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
(continued)
Core Sales Growth, Core Sales Growth Including Cytiva and Base Business Core Sales Growth
% Change Three-Month Period Ended December 31, 2021 vs. Comparable 2020 Period
% Change Year Ended December 31, 2021 vs. Comparable 2020 Period
Total sales growth (GAAP)20.5 %32.0 %
Impact of:
Acquisitions/divestitures(2.0)(7.5)
Currency exchange rates 1.0 (1.5)
Core sales growth (non-GAAP)19.5 %23.0 %
Impact of Cytiva sales growth (net of divested product lines)2.0 
Core sales growth including Cytiva (non-GAAP)25.0 %
Impact of COVID-related tailwinds(9.5)(13.5)
Base business core sales growth (non-GAAP)10.0 %11.5 %
Note: Danaher calculates period-to-period core sales growth including Cytiva by adding Cytiva sales to core sales for both the baseline and current periods. Beginning in the second quarter of 2021, Cytiva sales are included in core sales, and therefore the measure “core sales growth including Cytiva” is no longer provided for quarterly periods beginning with the second quarter of 2021. Therefore, the impact of Cytiva sales growth represents only the impact of Cytiva sales in the first quarter of 2021, prior to the inclusion of Cytiva sales in core sales. Impact of COVID-related tailwinds includes revenue from COVID-19 related testing and revenues related to products that support the pursuit and production of COVID-19 related treatments and vaccines.
Forecasted Core Sales Growth and Base Business Core Sales Growth 4
% Change Three-Month Period Ending April 1, 2022 vs. Comparable 2021 Period% Change Year Ending December 31, 2022 vs. Comparable 2021 Period
Core sales growth (non-GAAP)~10%+Mid-single digit
Impact of COVID-19 related testing(Low-single digit)+Low-single digit
Base business core sales growth (non-GAAP)+High-single digit+High-single digit
4    We do not reconcile these measures to the comparable GAAP measure because of the inherent difficulty in predicting and estimating the future impact and timing of currency translation, acquisitions and divested product lines, which would be reflected in any forecasted GAAP revenue.
Note: While we expect overall demand for the Company’s COVID-19 related products to moderate as and to the extent the pandemic subsides, as the pandemic evolves toward endemic status we believe a level of demand for the Company’s products that support COVID-19 related vaccines and therapeutics (including initiatives that seek to prevent or mitigate similar, future pandemics) and COVID-19 testing will continue. However, on a relative basis, we expect the level of ongoing demand for products supporting COVID-19 testing will be subject to more fluctuations in demand than the level of demand for products supporting COVID-19 related vaccines and therapeutics. Therefore, beginning with the first quarter of 2022, in addition to disclosing core revenue growth (as defined below), we will also disclose “base business core revenue growth” on a basis that excludes revenues related to COVID-19 testing and includes revenues from products that support COVID-19 related vaccines and therapeutics. We believe this additional measure will provide useful information to investors by facilitating period-to-period comparisons of our financial performance and identifying underlying growth trends in the Company’s business that otherwise may be obscured by fluctuations in demand for COVID-19 testing as a result of the pandemic.

See the accompanying Notes to Reconciliation of GAAP to Non-GAAP Financial Measures
4

DANAHER CORPORATION
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
(continued)
Free Cash Flow from Continuing Operations
($ in millions)
Year EndedYear-over-Year Change
December 31, 2021December 31, 2020
Total Cash Flows from Continuing Operations:
Total cash provided by operating activities from continuing operations (GAAP)$8,358 $6,215 
Total cash used in investing activities from continuing operations (GAAP)$(12,987)$(21,239)
Total cash provided by financing activities from continuing operations (GAAP)$1,295 $1,006 
Free Cash Flow from Continuing Operations:
Total cash provided by operating activities from continuing operations (GAAP)$8,358 $6,215 ~34.5%
Less: payments for additions to property, plant & equipment (capital expenditures) from continuing operations (GAAP)(1,294)(791)
Plus: proceeds from sales of property, plant & equipment (capital disposals) from continuing operations (GAAP)13 2 
Free cash flow from continuing operations (non-GAAP)$7,077 $5,426 ~30.5%
We define free cash flow as operating cash flows from continuing operations, less payments for additions to property, plant and equipment from continuing operations (“capital expenditures”) plus the proceeds from sales of plant, property and equipment from continuing operations (“capital disposals”). All amounts presented above reflect only continuing operations.                                                                                                                                            

See the accompanying Notes to Reconciliation of GAAP to Non-GAAP Financial Measures

5

DANAHER CORPORATION
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
(continued)
Notes to Reconciliation of GAAP to Non-GAAP Financial Measures
A    Amortization of acquisition-related intangible assets in the following historical periods ($ in millions) (only the pretax amounts set forth below are reflected in the amortization line item above):
Three-Month Period EndedYear Ended
December 31, 2021December 31, 2020December 31, 2021December 31, 2020
Pretax$394 $336 $1,450 $1,138 
After-tax315 270 1,157 915 
B    Costs incurred for fair value adjustments to inventory related to the acquisition of Aldevron in the three-month period ended December 31, 2021, ($13 million pretax as reported in this line item, $10 million after-tax). Costs incurred for fair value adjustments to inventory and deferred revenue and transaction costs deemed significant related to the acquisitions of Cytiva and Aldevron in the year ended December 31, 2021, ($104 million pretax as reported in this line item, $82 million after-tax). Costs incurred for fair value adjustments to inventory and deferred revenue related to the acquisition of Cytiva in the three-month period ended December 31, 2020, ($49 million pretax as reported in this line item, $39 million after-tax) and fair value adjustments to inventory and deferred revenue, transaction costs deemed significant and integration preparation costs related to the acquisition of Cytiva for the year ended December 31, 2020, ($568 million pretax as reported in this line item, $450 million after-tax). The Company deems acquisition-related transaction costs incurred in a given period to be significant (generally relating to the Company’s larger acquisitions) if it determines that such costs exceed the range of acquisition-related transaction costs typical for Danaher in a given period.
C    Impairment charges related to a trade name in the Diagnostics segment recorded in the year ended December 31, 2021, ($10 million pretax as reported in this line item, $8 million after-tax). Impairment charges related to a facility in the Diagnostics segment and trade names and other intangibles assets in the Environmental & Applied Solutions segment recorded in the year ended December 31, 2020, ($22 million pretax as reported in this line item, $17 million after-tax).
D    Net gains/losses on the Company's equity and limited partnership investments in the following historical periods (in $ millions) (only the pretax amounts set forth below are reflected in the fair value net gains/losses on investments line above):
Three-Month Period EndedYear Ended
December 31, 2021December 31, 2020December 31, 2021December 31, 2020
Pretax (gain)/loss$(71)$(31)$(401)$(18)
After-tax (gain)/loss(57)(24)(315)(14)
E    Gain on disposition of certain product lines in the year ended December 31, 2021, ($13 million pretax as reported in this line item, $10 million after-tax). Gain on disposition of certain product lines in the year ended December 31, 2020, ($455 million pretax as reported in this line item, $305 million after-tax).
F    Expense related to the modification and partial termination of prior commercial arrangements and resolution of an associated litigation in the year ended December 31, 2021, ($547 million pretax as reported in this line item, $415 million after-tax).
G    Loss on early extinguishment of debt resulting from “make-whole” payments and deferred costs associated with the retirement of the 2025 Euronotes in both the three-month period and the year ended December 31, 2021, ($96 million pretax as reported in this line item, $73 million after-tax). Loss on early extinguishment of debt resulting from “make-whole” payments and deferred costs associated with the retirement of the 2022 Euronotes in both the three-month period and the year ended December 31, 2020, ($26 million pretax as reported in this line item, $20 million after-tax).
H    This line item reflects the aggregate tax effect of all nontax adjustments reflected in the preceding line items of the table. In addition, the footnotes above indicate the after-tax amount of each individual adjustment item. Danaher estimates the tax effect of each adjustment item by applying Danaher’s overall estimated effective tax rate to the pretax amount, unless the nature of the item and/or the tax jurisdiction in which the item has been recorded requires application of a specific tax rate or tax treatment, in which case the tax effect of such item is estimated by applying such specific tax rate or tax treatment. The MCPS dividends are not tax deductible and therefore the tax effect of the adjustments does not include any tax impact of the MCPS dividends.
I    Discrete tax adjustments and other tax-related adjustments for both the three-month period and year ended December 31, 2021, include the impact of net discrete tax benefits of $120 million (or $0.16 per diluted common share), and $263 million (or $0.35 per diluted common share), respectively, related primarily to release of reserves for uncertain tax positions due to the expiration of statutes of limitation and audit settlements, excess tax benefits from stock-based compensation and the mix of earnings between the U.S. and certain jurisdictions with lower overall tax rates, net of changes in estimates associated
6

DANAHER CORPORATION
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
(continued)
with prior period uncertain tax positions. Discrete tax adjustments and other tax-related adjustments for the year ended December 31, 2020, include the impact of net discrete tax benefits of $85 million (or $0.12 per diluted common share) related primarily related to the release of reserves for uncertain tax positions from audit settlements and expiration of statutes of limitation and excess tax benefits from stock-based compensation, partially offset by a higher tax rate associated with the gain on the divestiture of certain product lines in the Life Sciences segment and changes in estimates associated with prior period uncertain tax positions. The Company anticipates excess tax benefits from stock compensation of approximately $7 million per quarter and therefore excludes benefits in excess of this amount in the calculation of adjusted diluted net earnings from continuing operations per common share.
J    In March 2019, the Company issued $1.65 billion in aggregate liquidation preference of 4.75% MCPS Series A. In May 2020, the Company issued $1.72 billion in aggregate liquidation preference of 5.0% MCPS Series B. Dividends on the MCPS Series A and Series B are payable on a cumulative basis at an annual rate of 4.75% and 5.0%, respectively, on the liquidation preference of $1,000 per share. Unless earlier converted, each share of MCPS Series A will automatically convert on April 15, 2022 into between 6.6611 and 8.1598 shares of Danaher’s common stock, subject to further anti-dilution adjustments. Unless earlier converted, each share of MCPS Series B will automatically convert on April 15, 2023 into between 5.0103 and 6.1376 shares of Danaher’s common stock, subject to further anti-dilution adjustments. The number of shares of Danaher’s common stock issuable on conversion of the MCPS will be determined based on the VWAP) per share of the Company's common stock over the 20 consecutive trading day period beginning on, and including, the 21st scheduled trading day immediately before April 15, 2022 and April 15, 2023 for the MCPS Series A and Series B, respectively. For the calculation of net earnings per common share from continuing operations, the impact of the dilutive MCPS is calculated under the if-converted method and the related MCPS dividends are excluded. For the purposes of calculating adjusted earnings per common share from continuing operations, the Company has excluded the paid and anticipated MCPS cash dividends and assumed the “if-converted” method of share dilution (the incremental shares of common stock deemed outstanding applying the “if-converted” method of calculating share dilution only with respect to any MCPS the conversion of which would be dilutive in the particular period are referred to as the “Converted Shares”) for any MCPS that were anti-dilutive for the given period. For additional information about the impact of the MCPS on the calculation of diluted EPS, see note 2 in the Adjusted Average Common Stock and Common Equivalent Diluted Shares Outstanding table above.

7

Statement Regarding Non-GAAP Measures
Each of the non-GAAP measures set forth above should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP measure, and may not be comparable to similarly titled measures reported by other companies.  Management believes that these measures provide useful information to investors by offering additional ways of viewing Danaher Corporation’s (“Danaher” or the “Company”) results that, when reconciled to the corresponding GAAP measure, help our investors to:
•with respect to Adjusted Diluted Net Earnings Per Common Share from Continuing Operations, understand the long-term profitability trends of our business and compare our profitability to prior and future periods and to our peers;
•with respect to core sales and related sales measures, identify underlying growth trends in our business and compare our sales performance with prior and future periods and to our peers; and
•with respect to free cash flow from continuing operations and related cash flow measures (the “FCF Measure”), understand Danaher’s ability to generate cash without external financings, strengthen its balance sheet, invest in its business and grow its business through acquisitions and other strategic opportunities (although a limitation of free cash flow is that it does not take into account the Company’s debt service requirements and other non-discretionary expenditures, and as a result the entire free cash flow amount is not necessarily available for discretionary expenditures).
We also present core sales on a basis that includes sales attributable to Cytiva (formerly the Biopharma Business of General Electric Company’s (“GE”) Life Sciences business), which Danaher acquired from GE on March 31, 2020. Historically Danaher has calculated core sales solely on a basis that excludes sales from acquired businesses recorded prior to the first anniversary of the acquisition. However, given Cytiva’s significant size and historical core sales growth rate, in each case compared to Danaher’s existing businesses, management believes it is appropriate to also present core sales on a basis that includes Cytiva sales. Management believes this presentation provides useful information to investors by demonstrating beginning immediately after the acquisition Cytiva’s impact on the Company’s growth profile, rather than waiting to demonstrate such impact 12 months after the acquisition when Cytiva would normally have been included in Danaher’s core sales calculation. Danaher calculates period-to-period core sales growth including Cytiva by adding to the baseline period sales Cytiva’s historical sales from such period (when it was owned by GE), net of the sales of the Company product lines divested in 2020 to obtain regulatory approval to acquire Cytiva (“Cytiva sales”) and also adding the Cytiva sales to the current period. Beginning in the second quarter of 2021, Cytiva sales are included in core sales, and therefore we no longer provide the measure “core sales including Cytiva” for quarterly periods beginning with the second quarter of 2021. We also present “base business” core revenue growth to demonstrate our core revenue growth and our core revenue growth including Cytiva excluding core sales growth directly attributable to COVID-19 and its impact.
While we expect overall demand for the Company’s COVID-19 related products to moderate as and to the extent the pandemic subsides, as the pandemic evolves toward endemic status we believe a level of demand for the Company’s products that support COVID-19 related vaccines and therapeutics (including initiatives that seek to prevent or mitigate similar, future pandemics) and COVID-19 testing will continue. However, on a relative basis, we expect the level of ongoing demand for products supporting COVID-19 testing will be subject to more fluctuations in demand than the level of demand for products supporting COVID-19 related vaccines and therapeutics. Therefore, beginning with the first quarter of 2022, in addition to disclosing core revenue growth (as defined below), we will also disclose “base business core revenue growth” on a basis that excludes revenues related to COVID-19 testing and includes revenues from products that support COVID-19 related vaccines and therapeutics. We believe this additional measure will provide useful information to investors by facilitating period-to-period comparisons of our financial performance and identifying underlying growth trends in the Company’s business that otherwise may be obscured by fluctuations in demand for COVID-19 testing as a result of the pandemic.
Management uses these non-GAAP measures to measure the Company’s operating and financial performance, and uses core sales and non-GAAP measures similar to Adjusted Diluted Net Earnings Per Common Share from Continuing Operations and the FCF Measure in the Company’s executive compensation program.
The items excluded from the non-GAAP measures set forth above have been excluded for the following reasons:
•With respect to Adjusted Diluted Net Earnings Per Common Share from Continuing Operations:
◦Amortization of Intangible Assets. We exclude the amortization of acquisition-related intangible assets because the amount and timing of such charges are significantly impacted by the timing, size, number and nature of the acquisitions we consummate. While we have a history of significant acquisition activity we do not acquire businesses on a predictable cycle, and the amount of an acquisition’s purchase price
8

allocated to intangible assets and related amortization term are unique to each acquisition and can vary significantly from acquisition to acquisition. Exclusion of this amortization expense facilitates more consistent comparisons of operating results over time between our newly acquired and long-held businesses, and with both acquisitive and non-acquisitive peer companies. We believe however that it is important for investors to understand that such intangible assets contribute to sales generation and that intangible asset amortization related to past acquisitions will recur in future periods until such intangible assets have been fully amortized.
◦Restructuring Charges. We exclude costs incurred pursuant to discrete restructuring plans that are fundamentally different (in terms of the size, strategic nature and planning requirements, as well as the inconsistent frequency, of such plans) from the ongoing productivity improvements that result from application of the Danaher Business System. Because these restructuring plans are incremental to the core activities that arise in the ordinary course of our business and we believe are not indicative of Danaher’s ongoing operating costs in a given period, we exclude these costs to facilitate a more consistent comparison of operating results over time.
◦Other Adjustments. With respect to the other items excluded from Adjusted Diluted Net Earnings Per Common Share from Continuing Operations, we exclude these items because they are of a nature and/or size that occur with inconsistent frequency, occur for reasons that may be unrelated to Danaher's commercial performance during the period and/or we believe that such items may obscure underlying business trends and make comparisons of long-term performance difficult.
•With respect to adjusted average common stock and common equivalent shares outstanding, Danaher’s Mandatory Convertible Preferred Stock (“MCPS”) will mandatorily convert into Danaher common stock on the mandatory conversion date, which is expected to be April 15, 2022 and April 15, 2023 for the Series A and Series B MCPS, respectively, (unless converted or redeemed earlier in accordance with the terms of the applicable certificate of designations). With respect to the calculation of Adjusted Diluted Net Earnings Per Common Share from Continuing Operations, we apply the “if converted” method of share dilution to the MCPS Series A and B in all applicable periods irrespective of whether such preferred shares would be dilutive or anti-dilutive in the period. We believe this presentation provides useful information to investors by helping them understand what the net impact will be on Danaher’s earnings per share-related measures once the MCPS convert into Danaher common stock.
•With respect to core sales related measures, (1) we exclude the impact of currency translation because it is not under management’s control, is subject to volatility and can obscure underlying business trends, and (2) we exclude the effect of acquisitions (other than Cytiva, in the case of core sales including Cytiva and base business core sales) and divested product lines because the timing, size, number and nature of such transactions can vary significantly from period-to-period and between us and our peers, which we believe may obscure underlying business trends and make comparisons of long-term performance difficult.
•With respect to the FCF Measure, we exclude payments for additions to property, plant and equipment (net of the proceeds from capital disposals) to demonstrate the amount of operating cash flow for the period that remains after accounting for the Company’s capital expenditure requirements.
With respect to forecasted core sales related measures, we do not reconcile these measures to the comparable GAAP measure because of the inherent difficulty in predicting and estimating the future impact and timing of currency translation, acquisitions and divested product lines, which would be reflected in any forecasted GAAP revenue.
9

DANAHER CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS (unaudited)
($ in millions, except per share amount)
As of December 31
20212020
ASSETS
Current assets:
Cash and equivalents$2,586 $6,035 
Trade accounts receivable, less allowance for doubtful accounts of $124 as of December 31, 2021 and $132 as of December 31, 20204,631 4,045 
Inventories2,767 2,292 
Prepaid expenses and other current assets1,664 1,430 
Total current assets11,648 13,802 
Property, plant and equipment, net3,790 3,262 
Other long-term assets3,719 2,395 
Goodwill41,184 35,420 
Other intangible assets, net22,843 21,282 
Total assets$83,184 $76,161 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Notes payable and current portion of long-term debt$8 $11 
Trade accounts payable2,569 2,049 
Accrued expenses and other liabilities5,563 5,342 
Total current liabilities8,140 7,402 
Other long-term liabilities7,699 7,789 
Long-term debt22,168 21,193 
Stockholders’ equity:
Preferred stock, no par value, 15.0 million shares authorized; 1.65 million shares of 4.75% Mandatory Convertible Preferred Stock, Series A, issued and outstanding as of December 31, 2021 and December 31, 2020; 1.72 million shares of 5.00% Mandatory Convertible Preferred Stock, Series B, issued and outstanding as of December 31, 2021 and December 31, 20203,268 3,268 
Common stock - $0.01 par value, 2.0 billion shares authorized; 855.7 million issued and 715.0 million outstanding as of December 31, 2021; 851.3 million issued and 711.0 million outstanding as of December 31, 20209 9 
Additional paid-in capital10,090 9,698 
Retained earnings32,827 27,159 
Accumulated other comprehensive income (loss)(1,027)(368)
Total Danaher stockholders’ equity45,167 39,766 
Noncontrolling interests10 11 
Total stockholders’ equity45,177 39,777 
Total liabilities and stockholders’ equity$83,184 $76,161 
This information is presented for reference only. Final audited financial statements will include footnotes, which should be referenced when available, to more fully understand the contents of this information.
10

DANAHER CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF EARNINGS (unaudited)
($ and shares in millions, except per share amounts)
 Three-Month Period EndedYear Ended
 December 31, 2021December 31, 2020December 31, 2021December 31, 2020
Sales$8,148 $6,760 $29,453 $22,284 
Cost of sales(3,205)(2,806)(11,501)(9,809)
Gross profit4,943 3,954 17,952 12,475 
Operating costs:
Selling, general and administrative expenses(2,294)(1,957)(8,198)(6,896)
Research and development expenses(495)(396)(1,742)(1,348)
Other operating expenses— — (547)— 
Operating profit2,154 1,601 7,465 4,231 
Nonoperating income (expense):
Other income (expense), net82 35 456 494 
Loss on early extinguishment of borrowings(96)(26)(96)(26)
Interest expense(56)(72)(238)(275)
Interest income1 4 11 71 
Earnings from continuing operations before income taxes2,085 1,542 7,598 4,495 
Income taxes(297)(301)(1,251)(849)
Net earnings from continuing operations1,788 1,241 6,347 3,646 
Earnings from discontinued operations, net of income taxes— — 86 — 
Net earnings1,788 1,241 6,433 3,646 
Mandatory convertible preferred stock dividends(41)(41)(164)(136)
Net earnings attributable to common stockholders$1,747 $1,200 $6,269 $3,510 
Net earnings per common share from continuing operations:
Basic$2.44 $1.69 $8.65 $4.97 
Diluted$2.39 $1.66 $8.50 $4.89 
(a)
Net earnings per common share from discontinued operations:
Basic$— $— $0.12 $— 
Diluted$— $— $0.12 $— 
Net earnings per common share:
Basic$2.44 $1.69 $8.77 $4.97 
Diluted$2.39 $1.66 $8.61 
(b)
$4.89 
(a)
Average common stock and common equivalent shares outstanding:
Basic715.6 711.6 714.6 706.2 
Diluted738.4 724.5 736.8 718.7 
(a) Net earnings per common share amounts for the relevant three-month periods do not add to the full year amounts due to rounding.
(b) Net earnings per common share amount does not add due to rounding.

This information is presented for reference only. Final audited financial statements will include footnotes, which should be referenced when available, to more fully understand the contents of this information.
11

DANAHER CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)
($ in millions)
Year Ended December 31
20212020
Cash flows from operating activities:
Net earnings$6,433 $3,646 
Less: earnings from discontinued operations, net of income taxes(86)— 
Net earnings from continuing operations6,347 3,646 
Noncash items:
Depreciation718 637 
Amortization of intangible assets1,450 1,138 
Amortization of acquisition-related inventory fair value step-up59 457 
Stock-based compensation expense218 187 
Contract settlement expense542 — 
Pretax loss on early extinguishment of borrowings96 26 
Pretax gain on sale of product lines and investment (gains) losses(414)(455)
Change in deferred income taxes(229)518 
Change in trade accounts receivable, net(611)(264)
Change in inventories(502)(123)
Change in trade accounts payable549 227 
Change in prepaid expenses and other assets(4)102 
Change in accrued expenses and other liabilities139 119 
Total operating cash provided by continuing operations8,358 6,215 
Total operating cash (used in) provided by discontinued operations— (7)
Net cash provided by operating activities8,358 6,208 
Cash flows from investing activities:
Cash paid for acquisitions(10,961)(20,971)
Payments for additions to property, plant and equipment(1,294)(791)
Proceeds from sales of property, plant and equipment13 2 
Payments for purchases of investments(934)(342)
Proceeds from sales of investments126 13 
Proceeds from sale of product lines26 826 
All other investing activities37 24 
Total cash used in investing activities from continuing operations(12,987)(21,239)
Cash flows from financing activities:
Proceeds from the issuance of common stock in connection with stock-based compensation86 153 
Proceeds from the public offering of common stock, net of issuance costs— 1,729 
Proceeds from the public offering of preferred stock, net of issuance costs— 1,668 
Payment of dividends(742)(615)
Net proceeds from (repayments of) borrowings (maturities of 90 days or less)2,265 (4,637)
Proceeds from borrowings (maturities longer than 90 days)984 8,670 
Repayments of borrowings (maturities longer than 90 days)(1,186)(5,933)
Make-whole premiums to redeem borrowings prior to maturity(96)(26)
All other financing activities(16)(3)
Total financing cash provided by continuing operations1,295 1,006 
Effect of exchange rate changes on cash and equivalents(115)148 
Net change in cash and equivalents(3,449)(13,877)
Beginning balance of cash and equivalents6,035 19,912 
Ending balance of cash and equivalents$2,586 $6,035 
This information is presented for reference only. Final audited financial statements will include footnotes, which should be referenced when available, to more fully understand the contents of this information.
12

DANAHER CORPORATION AND SUBSIDIARIES
SEGMENT INFORMATION (unaudited)
($ in millions)
Three-Month Period EndedYear Ended
December 31, 2021December 31, 2020December 31, 2021December 31, 2020
Sales:
Life Sciences$4,046 $3,361 $14,958 $10,576 
Diagnostics2,881 2,227 9,844 7,403 
Environmental & Applied Solutions1,221 1,172 4,651 4,305 
Total Company$8,148 $6,760 $29,453 $22,284 
Operating Profit:
Life Sciences$1,097 $811 $4,367 $2,054 
Diagnostics893 586 2,313 1,538 
Environmental & Applied Solutions233 272 1,054 979 
Other(69)(68)(269)(340)
Total Company$2,154 $1,601 $7,465 $4,231 
Operating Profit Margins:
Life Sciences27.1 %24.1 %29.2 %19.4 %
Diagnostics31.0 %26.3 %23.5 %20.8 %
Environmental & Applied Solutions19.1 %23.2 %22.7 %22.7 %
Total Company26.4 %23.7 %25.3 %19.0 %
This information is presented for reference only. Final audited financial statements will include footnotes, which should be referenced when available, to more fully understand the contents of this information.
13
 EX-101.SCH 3 dhr-20220127.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Document And Entity Information Document And Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 dhr-20220127_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 5 dhr-20220127_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Floating Rate Senior Notes due 2022 Floating Rate Senior Notes Due 2022 [Member] Floating Rate Senior Notes Due 2022 Member [Member] Entity Listings [Line Items] Entity Listings [Line Items] 1.200% Senior Notes due 2027 1.2% Senior Notes Due 2027 [Member] 1.2% Senior Notes Due 2027 [Member] Entity address, state Entity Address, State or Province Entity tax identification number Entity Tax Identification Number Title of 12(b) security Title of 12(b) Security 2.100% Senior Notes due 2026 2.1% Senior Notes Due 2026 [Member] 2.1% Senior Notes Due 2026 [Member] Entity file number Entity File Number Written communications Written Communications 0.200% Senior Notes due 2026 0.2% Senior Notes Due 2026 [Member] 0.2% Senior Notes Due 2026 [Member] Entity emerging growth company Entity Emerging Growth Company 1.700% Senior Notes due 2024 1.7% Senior Notes Due 2024 [Member] 1.7% Senior Notes Due 202 [Member] Soliciting material Soliciting Material 0.450% Senior Notes due 2028 0.45% Senior Notes Due 2028 [Member] 0.45% Senior Notes Due 2028 [Member] City area code City Area Code Entity incorporation, state Entity Incorporation, State or Country Code Entity address, address line one Entity Address, Address Line One Entity address, address line two Entity Address, Address Line Two Local phone number Local Phone Number Cover [Abstract] Cover [Abstract] 2.500% Senior Notes due 2030 2.5% Senior Notes Due 2030 [Member] 2.5% Senior Notes Due 2030 [Member] Entity Listings [Table] Entity Listings [Table] Pre-commencement tender offer Pre-commencement Tender Offer Common stock, $0.01 par value Common Stock [Member] Amendment flag Amendment Flag 4.75% Mandatory Convertible Preferred Stock, Series A, without par value Series A Preferred Stock [Member] Pre-commencement issuer tender offer Pre-commencement Issuer Tender Offer Trading symbol Trading Symbol Document period end date Document Period End Date Class of Stock [Domain] Class of Stock [Domain] Document type Document Type Class of Stock [Axis] Class of Stock [Axis] Entity registrant name Entity Registrant Name 1.350% Senior Notes due 2039 1.35% Senior Notes Due 2039 [Member] 1.35% Senior Notes Due 2039 [Member] 5.00% Mandatory Convertible Preferred Stock, Series B, without par value Series B Preferred Stock [Member] Entity address, city Entity Address, City or Town 1.800% Senior Notes due 2049 1.8% Senior Notes Due 2049 [Member] 1.8% Senior Notes Due 2049 [Member] Entity address, postal zip code Entity Address, Postal Zip Code 0.750% Senior Notes due 2031 0.75% Senior Notes Due 2031 [Member] 0.75% Senior Notes Due 2031 [Member] Entity central index key Entity Central Index Key Security exchange name Security Exchange Name EX-101.PRE 6 dhr-20220127_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 7 dhr-20220127_g1.jpg begin 644 dhr-20220127_g1.jpg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end GRAPHIC 8 dhrlogofor8ksa62.jpg begin 644 dhrlogofor8ksa62.jpg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end XML 9 R1.htm IDEA: XBRL DOCUMENT v3.21.4
Document And Entity Information Document And Entity Information
Jan. 27, 2022
Cover [Abstract]  
Document type 8-K
Document period end date Jan. 27, 2022
Entity registrant name DANAHER CORPORATION
Entity incorporation, state DE
Entity file number 001-08089
Entity tax identification number 59-1995548
Entity address, address line one 2200 Pennsylvania Avenue, N.W.,
Entity address, address line two Suite 800W
Entity address, city Washington,
Entity address, state DC
Entity address, postal zip code 20037-1701
City area code 202
Local phone number 828-0850
Written communications false
Soliciting material false
Pre-commencement tender offer false
Pre-commencement issuer tender offer false
Entity emerging growth company false
Amendment flag false
Entity central index key 0000313616
Common stock, $0.01 par value  
Entity Listings [Line Items]  
Title of 12(b) security Common stock, $0.01 par value
Trading symbol DHR
Security exchange name NYSE
4.75% Mandatory Convertible Preferred Stock, Series A, without par value  
Entity Listings [Line Items]  
Title of 12(b) security 4.75% Mandatory Convertible Preferred Stock, Series A, without par value
Trading symbol DHR.PRA
Security exchange name NYSE
5.00% Mandatory Convertible Preferred Stock, Series B, without par value  
Entity Listings [Line Items]  
Title of 12(b) security 5.00% Mandatory Convertible Preferred Stock, Series B, without par value
Trading symbol DHR.PRB
Security exchange name NYSE
Floating Rate Senior Notes due 2022  
Entity Listings [Line Items]  
Title of 12(b) security Floating Rate Senior Notes due 2022
Trading symbol DHR/22A
Security exchange name NYSE
1.700% Senior Notes due 2024  
Entity Listings [Line Items]  
Title of 12(b) security 1.700% Senior Notes due 2024
Trading symbol DHR 24
Security exchange name NYSE
0.200% Senior Notes due 2026  
Entity Listings [Line Items]  
Title of 12(b) security 0.200% Senior Notes due 2026
Trading symbol DHR/26
Security exchange name NYSE
2.100% Senior Notes due 2026  
Entity Listings [Line Items]  
Title of 12(b) security 2.100% Senior Notes due 2026
Trading symbol DHR 26
Security exchange name NYSE
1.200% Senior Notes due 2027  
Entity Listings [Line Items]  
Title of 12(b) security 1.200% Senior Notes due 2027
Trading symbol DHR/27
Security exchange name NYSE
0.450% Senior Notes due 2028  
Entity Listings [Line Items]  
Title of 12(b) security 0.450% Senior Notes due 2028
Trading symbol DHR/28
Security exchange name NYSE
2.500% Senior Notes due 2030  
Entity Listings [Line Items]  
Title of 12(b) security 2.500% Senior Notes due 2030
Trading symbol DHR 30
Security exchange name NYSE
0.750% Senior Notes due 2031  
Entity Listings [Line Items]  
Title of 12(b) security 0.750% Senior Notes due 2031
Trading symbol DHR/31
Security exchange name NYSE
1.350% Senior Notes due 2039  
Entity Listings [Line Items]  
Title of 12(b) security 1.350% Senior Notes due 2039
Trading symbol DHR/39
Security exchange name NYSE
1.800% Senior Notes due 2049  
Entity Listings [Line Items]  
Title of 12(b) security 1.800% Senior Notes due 2049
Trading symbol DHR/49
Security exchange name NYSE
XML 10 dhr-20220127_htm.xml IDEA: XBRL DOCUMENT 0000313616 2022-01-27 2022-01-27 0000313616 us-gaap:CommonStockMember 2022-01-27 2022-01-27 0000313616 us-gaap:SeriesAPreferredStockMember 2022-01-27 2022-01-27 0000313616 us-gaap:SeriesBPreferredStockMember 2022-01-27 2022-01-27 0000313616 dhr:FloatingRateSeniorNotesDue2022Member 2022-01-27 2022-01-27 0000313616 dhr:A1.7SeniorNotesDue2024Member 2022-01-27 2022-01-27 0000313616 dhr:A0.2SeniorNotesDue2026Member 2022-01-27 2022-01-27 0000313616 dhr:A2.1SeniorNotesDue2026Member 2022-01-27 2022-01-27 0000313616 dhr:A1.2SeniorNotesDue2027Member 2022-01-27 2022-01-27 0000313616 dhr:A0.45SeniorNotesDue2028Member 2022-01-27 2022-01-27 0000313616 dhr:A2.5SeniorNotesDue2030Member 2022-01-27 2022-01-27 0000313616 dhr:A0.75SeniorNotesDue2031Member 2022-01-27 2022-01-27 0000313616 dhr:A1.35SeniorNotesDue2039Member 2022-01-27 2022-01-27 0000313616 dhr:A1.8SeniorNotesDue2049Member 2022-01-27 2022-01-27 false 0000313616 8-K 2022-01-27 DANAHER CORPORATION DE 001-08089 59-1995548 2200 Pennsylvania Avenue, N.W., 20037-1701 Suite 800W Washington, DC 202 828-0850 false false false false Common stock, $0.01 par value DHR NYSE 4.75% Mandatory Convertible Preferred Stock, Series A, without par value DHR.PRA NYSE 5.00% Mandatory Convertible Preferred Stock, Series B, without par value DHR.PRB NYSE Floating Rate Senior Notes due 2022 DHR/22A NYSE 1.700% Senior Notes due 2024 DHR 24 NYSE 0.200% Senior Notes due 2026 DHR/26 NYSE 2.100% Senior Notes due 2026 DHR 26 NYSE 1.200% Senior Notes due 2027 DHR/27 NYSE 0.450% Senior Notes due 2028 DHR/28 NYSE 2.500% Senior Notes due 2030 DHR 30 NYSE 0.750% Senior Notes due 2031 DHR/31 NYSE 1.350% Senior Notes due 2039 DHR/39 NYSE 1.800% Senior Notes due 2049 DHR/49 NYSE false EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.4 html 14 118 1 false 13 0 false 0 false false R1.htm 0001001 - Document - Document And Entity Information Document And Entity Information Sheet http://www.danaher.com/role/DocumentAndEntityInformationDocumentAndEntityInformation Document And Entity Information Document And Entity Information Cover 1 false false All Reports Book All Reports dhr-20220127.htm dhr-20220127.xsd dhr-20220127_def.xml dhr-20220127_lab.xml dhr-20220127_pre.xml dhr-20220127xex991.htm dhr-20220127_g1.jpg http://xbrl.sec.gov/dei/2021 http://fasb.org/us-gaap/2021-01-31 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "dhr-20220127.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 14, "dts": { "definitionLink": { "local": [ "dhr-20220127_def.xml" ] }, "inline": { "local": [ "dhr-20220127.htm" ] }, "labelLink": { "local": [ "dhr-20220127_lab.xml" ] }, "presentationLink": { "local": [ "dhr-20220127_pre.xml" ] }, "schema": { "local": [ "dhr-20220127.xsd" ], "remote": [ "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" ] } }, "elementCount": 41, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 118, "memberCustom": 10, "memberStandard": 3, "nsprefix": "dhr", "nsuri": "http://www.danaher.com/20220127", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dhr-20220127.htm", "contextRef": "iddadcc8062764979b16432d5b4b5a87a_D20220127-20220127", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Document And Entity Information Document And Entity Information", "role": "http://www.danaher.com/role/DocumentAndEntityInformationDocumentAndEntityInformation", "shortName": "Document And Entity Information Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dhr-20220127.htm", "contextRef": "iddadcc8062764979b16432d5b4b5a87a_D20220127-20220127", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 13, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.danaher.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City area code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.danaher.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document period end date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.danaher.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.danaher.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity address, address line one" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.danaher.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity address, address line two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.danaher.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity address, city" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.danaher.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity address, postal zip code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.danaher.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity address, state" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.danaher.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity central index key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.danaher.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity emerging growth company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.danaher.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity file number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.danaher.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity incorporation, state" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.danaher.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityListingsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Listings [Line Items]", "terseLabel": "Entity Listings [Line Items]" } } }, "localname": "EntityListingsLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.danaher.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityListingsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container for exchange listing information for an entity", "label": "Entity Listings [Table]", "terseLabel": "Entity Listings [Table]" } } }, "localname": "EntityListingsTable", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.danaher.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity registrant name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.danaher.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity tax identification number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.danaher.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local phone number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.danaher.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement issuer tender offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.danaher.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement tender offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.danaher.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.danaher.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security exchange name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.danaher.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.danaher.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.danaher.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.danaher.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dhr_A0.2SeniorNotesDue2026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "0.2% Senior Notes Due 2026 [Member]", "label": "0.2% Senior Notes Due 2026 [Member]", "terseLabel": "0.200% Senior Notes due 2026" } } }, "localname": "A0.2SeniorNotesDue2026Member", "nsuri": "http://www.danaher.com/20220127", "presentation": [ "http://www.danaher.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dhr_A0.45SeniorNotesDue2028Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "0.45% Senior Notes Due 2028 [Member]", "label": "0.45% Senior Notes Due 2028 [Member]", "terseLabel": "0.450% Senior Notes due 2028" } } }, "localname": "A0.45SeniorNotesDue2028Member", "nsuri": "http://www.danaher.com/20220127", "presentation": [ "http://www.danaher.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dhr_A0.75SeniorNotesDue2031Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "0.75% Senior Notes Due 2031 [Member]", "label": "0.75% Senior Notes Due 2031 [Member]", "terseLabel": "0.750% Senior Notes due 2031" } } }, "localname": "A0.75SeniorNotesDue2031Member", "nsuri": "http://www.danaher.com/20220127", "presentation": [ "http://www.danaher.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dhr_A1.2SeniorNotesDue2027Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "1.2% Senior Notes Due 2027 [Member]", "label": "1.2% Senior Notes Due 2027 [Member]", "terseLabel": "1.200% Senior Notes due 2027" } } }, "localname": "A1.2SeniorNotesDue2027Member", "nsuri": "http://www.danaher.com/20220127", "presentation": [ "http://www.danaher.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dhr_A1.35SeniorNotesDue2039Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "1.35% Senior Notes Due 2039 [Member]", "label": "1.35% Senior Notes Due 2039 [Member]", "terseLabel": "1.350% Senior Notes due 2039" } } }, "localname": "A1.35SeniorNotesDue2039Member", "nsuri": "http://www.danaher.com/20220127", "presentation": [ "http://www.danaher.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dhr_A1.7SeniorNotesDue2024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "1.7% Senior Notes Due 202 [Member]", "label": "1.7% Senior Notes Due 2024 [Member]", "terseLabel": "1.700% Senior Notes due 2024" } } }, "localname": "A1.7SeniorNotesDue2024Member", "nsuri": "http://www.danaher.com/20220127", "presentation": [ "http://www.danaher.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dhr_A1.8SeniorNotesDue2049Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "1.8% Senior Notes Due 2049 [Member]", "label": "1.8% Senior Notes Due 2049 [Member]", "terseLabel": "1.800% Senior Notes due 2049" } } }, "localname": "A1.8SeniorNotesDue2049Member", "nsuri": "http://www.danaher.com/20220127", "presentation": [ "http://www.danaher.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dhr_A2.1SeniorNotesDue2026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2.1% Senior Notes Due 2026 [Member]", "label": "2.1% Senior Notes Due 2026 [Member]", "terseLabel": "2.100% Senior Notes due 2026" } } }, "localname": "A2.1SeniorNotesDue2026Member", "nsuri": "http://www.danaher.com/20220127", "presentation": [ "http://www.danaher.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dhr_A2.5SeniorNotesDue2030Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2.5% Senior Notes Due 2030 [Member]", "label": "2.5% Senior Notes Due 2030 [Member]", "terseLabel": "2.500% Senior Notes due 2030" } } }, "localname": "A2.5SeniorNotesDue2030Member", "nsuri": "http://www.danaher.com/20220127", "presentation": [ "http://www.danaher.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dhr_FloatingRateSeniorNotesDue2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Floating Rate Senior Notes Due 2022 Member [Member]", "label": "Floating Rate Senior Notes Due 2022 [Member]", "terseLabel": "Floating Rate Senior Notes due 2022" } } }, "localname": "FloatingRateSeniorNotesDue2022Member", "nsuri": "http://www.danaher.com/20220127", "presentation": [ "http://www.danaher.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.danaher.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common stock, $0.01 par value" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.danaher.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series A Preferred Stock [Member]", "terseLabel": "4.75%\u00a0Mandatory Convertible Preferred\u00a0Stock, Series A, without par value" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.danaher.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series B Preferred Stock [Member]", "terseLabel": "5.00%\u00a0Mandatory Convertible Preferred\u00a0Stock, Series B, without par value" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.danaher.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.danaher.com/role/DocumentAndEntityInformationDocumentAndEntityInformation" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 17 0000313616-22-000005-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000313616-22-000005-xbrl.zip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end